- 46 次围观
产品图片
货号/SKU
NR-52286
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-52286?? SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated(Inactivated Organisms)|SARS-Related Coronavirus 2|SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated|-60°C or colder|CDCAcknowledgment for publications should read "The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Heat Inactivated, NR-52286."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
NR-52286 is recommend for molecular assays. The current quality control testing for this item does not include immunological assays and it is not recommended that NR-52286 be used in this manner.
NR-52286 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing.
SARS-CoV-2, isolate USA-WA1/2020 was isolated from an oropharyngeal swab from a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Washington, USA.
The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced from the isolate (GISAID: EPI_ISL_404895) and after one passage in Vero cells – GenBank: MT020880). The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced after four passages in Vero cells in collaboration with Database for Reference Grade Microbial Sequences (FDA-ARGOS; GenBank: MT246667).
Intended Use:
NR-52286 is primarily intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE is determined by full and partial genomes and is an estimate for end-users to qualify assays on their platform and is subject to efficiency of RNA extraction. The estimated GE can also be used to make a dilution series to estimate level of detection. The heat inactivation procedure is known to damage viral RNA and large fragments are not easily amplified. The suitability of this product as a whole cell antigen preparation has not been assessed and may be influenced by the protein content largely contributed by the host cell and the fetal bovine serum used during virus propagation.
Inactivation Procedure:
Please refer to the Certificate of Analysis for the inactivation testing details.
Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA-WA1/2020. The vial should be centrifuged prior to opening.
Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.
NR-52286 is recommend for molecular assays. The current quality control testing for this item does not include immunological assays and it is not recommended that NR-52286 be used in this manner.
NR-52286 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing.
SARS-CoV-2, isolate USA-WA1/2020 was isolated from an oropharyngeal swab from a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Washington, USA.
The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced from the isolate (GISAID: EPI_ISL_404895) and after one passage in Vero cells – GenBank: MT020880). The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced after four passages in Vero cells in collaboration with Database for Reference Grade Microbial Sequences (FDA-ARGOS; GenBank: MT246667).
Intended Use:
NR-52286 is primarily intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE is determined by full and partial genomes and is an estimate for end-users to qualify assays on their platform and is subject to efficiency of RNA extraction. The estimated GE can also be used to make a dilution series to estimate level of detection. The heat inactivation procedure is known to damage viral RNA and large fragments are not easily amplified. The suitability of this product as a whole cell antigen preparation has not been assessed and may be influenced by the protein content largely contributed by the host cell and the fetal bovine serum used during virus propagation.
Inactivation Procedure:
Please refer to the Certificate of Analysis for the inactivation testing details.
Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA-WA1/2020. The vial should be centrifuged prior to opening.
Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送至NIAID进行批准.
推荐NR-52286用于分子测定.该项目的当前质量控制测试不包括免疫测定，不建议以这种方式使用NR-52286.
NR-52286是重症急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的制备，分离出通过加热至65℃而灭活的US-WA1 / 2020 30分钟并在瓶中稀释.
SARS-COV-2，孤立USA-WA1 / 2020从患有最近从旅行到中国受影响地区的呼吸疾病的口咽疾病中分离出来的患者，并在2020年1月开始出现临床疾病（Covid-19）华盛顿，美国.
SARS-COV-2的完整基因组，USA-WA1 / 2020已从孤立（GISAID：EPI_ISL_404895）和VERO Cells中的一段通道后测序 - Genbank： mt020880 ）. SARS-CoV-2的完整基因组，USA-WA1 / 2020在与参考级微生物序列的数据库合作的vero细胞中的四次通道后已经测序（FDA-Argos; Genbank： mt246667 ）.
预期用途： NR-52286主要用于使用
分子测定或可用作过程（工作流程）控制（例如：
病毒RNA通过QPCR扩增过程提取）.请参考
灭活前传染性滴度分析证书
通过液滴数码PCR定量后失活的基因组当量（GE）量化
为您的特定批次. GE由完全和部分基因组确定，是
最终用户估算到他们平台上的测定并受到影响
RNA提取的效率.估计的GE也可以用来制作一个
稀释系列以估计检测水平.热灭活程序
已知损害病毒RNA，大片段不易扩增. ＆nbsp的适用性; 本产品作为整个细胞
抗原制剂 尚未评估 ，也可能是
受蛋白质含量的影响大部分由宿主细胞和宿主细胞贡献
病毒繁殖期间使用的胎牛血清.＆nbsp; ＆nbsp; 灭活程序：请参阅
灭活测试细节分析证书.＆nbsp; 每个小瓶含有大约0.25ml的热灭活，澄清和稀释的细胞裂解物和来自感染SARS-COV-2的Vero E6细胞的上清液，隔离USA-WA1 / 2020.小瓶应在开放前离心.
注意：此时不知道该准备的长期稳定性.建议用户在收到三个月内使用，确认产品的活动.您还可以联系Bei资源以获取更新的稳定信息.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-06-17
2022-06-17
2021-12-02
2022-03-22
2021-12-02
2022-04-01
2021-12-21
2025-03-18
2024-01-21
2021-10-31
2021-12-02
2021-12-21
2022-04-01